Analysts are intrested in these 5 stocks: ( (MELI) ), ( (TMUS) ), ( (CRBP) ), ( (CLS) ) and ( (ELV) ). Here is a breakdown of their recent ratings and the rationale behind them.
Claim 55% Off TipRanks
New trading tool for CLS bullsMercadoLibre is drawing more cautious views as analyst Kaio Da Prato at UBS cuts the stock to Hold and trims the price target to $2,050. He argues the Latin American e‑commerce and fintech leader is still in an early investment phase, with spending on logistics, credit cards, and cross‑border trade likely to weigh on margins until at least 2027–2028.
While revenue and gross merchandise volume are expected to keep rising, higher costs for shipping, marketing, and credit losses mean profit estimates have been reduced. The stock now trades at earnings multiples that the analyst sees as fair versus its peers, limiting near‑term upside unless growth or advertising penetration surprises positively.
T‑Mobile US is back in favor with Oppenheimer’s Timothy Horan, who upgrades the shares to Buy and sets a $260 price target. The call rests on the carrier’s ability to use AI and digital tools to lift prices, hold down costs, and grow new services without chasing raw subscriber counts.
The analyst highlights solid first‑quarter numbers, rising free cash flow, and an attractive valuation at about an 11% projected 2027 free‑cash‑flow yield. Potential upside catalysts include continued buybacks, disciplined fiber joint ventures, edge‑computing opportunities, and even a future deal with Deutsche Telekom that could come with a premium for minority investors.
Corbus Pharmaceuticals is emerging as a speculative biotech favorite, with analyst Paul Jeng initiating coverage at Buy and a $45 target. The story centers on CRB‑701, a next‑generation antibody‑drug conjugate aimed at certain head and neck and cervical cancers, designed to be more tolerable yet potent than current Nectin‑4 therapies.
Jeng believes the market is undervaluing Corbus, given its small market cap and upcoming data at ASCO that could clarify the drug’s path in HPV‑positive head and neck cancer. A separate obesity candidate, CRB‑913, adds higher‑risk but meaningful upside potential, creating a wide range of outcomes that appeals to risk‑tolerant investors.
Celestica has won over skeptics as analyst John Shao upgrades the stock to Buy and raises his price target to $430. After a recent 14% sell‑off despite strong results, he now sees the pullback as an attractive entry point into a company with improving visibility and accelerating growth.
The upgraded view is built on sharply higher 2027 revenue and earnings forecasts, supported by new program wins and planned capacity expansion. Shao’s prior concerns about valuation have eased as guidance strengthened, and he argues it is hard to justify a neutral stance while projecting such robust performance.
Elevance Health is also getting an upgrade, with Kevin Fischbeck moving the insurer to Buy and boosting the price objective to $435. He sees 2026 as the trough year for Medicaid margins, which are currently dragging down earnings but are expected to normalize as states reset reimbursement rates over the next few years.
As Medicaid profitability recovers and the rest of Elevance’s diversified operations grow at a healthy clip, Fischbeck estimates roughly $10 of earnings per share upside tied to this margin rebound. While near‑term uncertainty remains around medical trends and exchange business, he views Elevance as a relatively lower‑risk way to play the theme of improving Medicaid economics.